Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 5:09 pm Purchase | 2026-03-31 | 13G | TAYSHA GENE THERAPIES INC TSHA | Vestal Point Capital, LP | 18,000,000 6.300% | 4,250,000 (+30.91%) | Filing History |
| 2026-05-15 5:06 pm Purchase | 2026-03-31 | 13G | BICARA THERAPEUTICS INC BCAX | Vestal Point Capital, LP | 5,425,000 8.300% | 1,850,000 (+51.75%) | Filing History |
| 2026-05-15 5:05 pm Sale | 2026-03-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Vestal Point Capital, LP | 3,250,000 5.400% | -580,000 (-15.14%) | Filing History |
| 2026-05-15 5:05 pm Sale | 2026-03-31 | 13G | ALTO NEUROSCIENCE INC ANRO | Vestal Point Capital, LP | 2,064,075 6.500% | -420,925 (-16.94%) | Filing History |
| 2026-05-15 5:03 pm Sale | 2026-03-31 | 13G | IMMATICS N V IMTX | Vestal Point Capital, LP | 6,175,000 4.600% | -100,000 (-1.59%) | Filing History |
| 2026-05-15 5:03 pm Sale | 2026-03-31 | 13G | ARCELLX INC ACLX | Vestal Point Capital, LP | 0 0.000% | -2,925,000 (Position Closed) | Filing History |
| 2026-05-15 5:02 pm Sale | 2026-03-31 | 13G | DAY ONE BIOPHARMACEUTICALS INC DAWN | Vestal Point Capital, LP | 0 0.000% | -5,200,000 (Position Closed) | Filing History |
| 2026-05-15 5:02 pm Purchase | 2026-03-31 | 13G | BRIGHT MINDS BIOSCIENCES INC C DRUG | Vestal Point Capital, LP | 492,319 5.000% | 492,319 (New Position) | Filing History |
| 2026-05-15 5:01 pm Purchase | 2026-03-31 | 13G | NURIX THERAPEUTICS INC NRIX | Vestal Point Capital, LP | 6,500,000 6.300% | 6,500,000 (New Position) | Filing History |
| 2026-05-15 5:00 pm Purchase | 2026-03-31 | 13G | APREA THERAPEUTICS INC APRE | Vestal Point Capital, LP | 22,654,832 9.900% | 22,654,832 (New Position) | Filing History |
| 2026-05-15 5:00 pm Purchase | 2026-03-31 | 13G | IMMUNOCORE HLDGS PLC ADS IMCR | Vestal Point Capital, LP | 2,766,868 5.500% | 2,766,868 (New Position) | Filing History |
| 2026-02-17 4:10 pm Sale | 2025-12-31 | 13G | BICARA THERAPEUTICS INC BCAX | Vestal Point Capital, LP | 3,575,000 6.500% | -1,425,000 (-28.50%) | Filing History |
| 2026-02-17 4:10 pm Sale | 2025-12-31 | 13G | ASTRIA THERAPEUTICS INC ATXS | Vestal Point Capital, LP | 0 0.000% | -4,956,000 (Position Closed) | Filing History |
| 2026-02-17 4:09 pm Sale | 2025-12-31 | 13G | BLACK DIAMOND THERAPEUTICS INC BDTX | Vestal Point Capital, LP | 870,000 1.500% | -4,158,500 (-82.70%) | Filing History |
| 2026-02-17 4:08 pm Sale | 2025-12-31 | 13G | APPLIED THERAPEUTICS INC APLT | Vestal Point Capital, LP | 0 0.000% | -11,500,000 (Position Closed) | Filing History |
| 2026-02-17 4:08 pm Purchase | 2025-12-31 | 13G | SOLID BIOSCIENCES INC SLDB | Vestal Point Capital, LP | 5,815,000 7.500% | 4,061,442 (+231.61%) | Filing History |
| 2026-02-17 4:07 pm Purchase | 2025-12-31 | 13G | TAYSHA GENE THERAPIES INC TSHA | Vestal Point Capital, LP | 13,750,000 5.000% | 13,750,000 (New Position) | Filing History |
| 2026-02-17 4:07 pm Purchase | 2025-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Vestal Point Capital, LP | 3,830,000 6.500% | 3,830,000 (New Position) | Filing History |
| 2026-02-17 4:06 pm Purchase | 2025-12-31 | 13G | DAY ONE BIOPHARMACEUTICALS INC DAWN | Vestal Point Capital, LP | 5,200,000 5.100% | 5,200,000 (New Position) | Filing History |
| 2026-02-17 4:06 pm Purchase | 2025-12-31 | 13G | CRESCENT BIOPHARMA, INC CBIO | Vestal Point Capital, LP | 1,500,000 5.400% | 1,500,000 (New Position) | Filing History |